TELA Bio, Inc. TELA
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-13.97
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $80.3M | -$38.8M | $54.3M | -$28.7M | $6.3M |
| 2024 | $69.3M | -$37.8M | $46.5M | -$42.6M | $28.5M |
| 2023 | $58.5M | -$46.7M | $40.1M | -$41.5M | $18.9M |
| 2022 | $41.4M | -$44.3M | $27.0M | -$41.6M | $14.3M |
| 2021 | $29.5M | -$33.3M | $18.8M | -$31.1M | $20.1M |
| 2020 | $18.2M | -$28.8M | $11.2M | -$24.6M | $49.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Capper Joseph H | director | 2026-06-09 | Grant | 11,925 | — |
| Capper Joseph H | director | 2026-06-09 | Grant | 11,675 | — |
| Plovanic William J. | director | 2026-06-09 | Grant | 11,675 | — |
| NEELS GUIDO J | director | 2026-06-09 | Grant | 11,925 | — |
| NEELS GUIDO J | director | 2026-06-09 | Grant | 11,675 | — |
| THOMAS PAUL | director | 2026-06-09 | Grant | 11,925 | — |
| THOMAS PAUL | director | 2026-06-09 | Grant | 11,675 | — |
| Rocchio Betty Jo | director | 2026-06-09 | Grant | 11,675 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.97 (distress)
- Working capital / assets 0.708
- Retained earnings / assets -4.883
- EBIT / assets -0.415
- Equity / liabilities 0.084
Source: SEC EDGAR filings · CIK 0001561921 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.